- Oncology Drug Advisory Committee
-
The Oncology Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat cancer.
References
The 2011 Advisory Committee Tentative Meetings schedule: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
